Storm brews around Aduhelm as FDA re­quests probe; Dis­sect­ing pipeline dis­as­ters; Bob Nelsen is go­ing Re­al­ly Big; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

As the bio­phar­ma in­dus­try booms, man­u­fac­tur­ing drugs in the quan­ti­ty and qual­i­ty re­quired are be­com­ing in­creas­ing­ly cru­cial. If you’re in­ter­est­ed in track­ing the lat­est de­vel­op­ments in that space, Kyle Blanken­ship and Josh Sul­li­van have you cov­ered in the week­ly End­points Man­u­fac­tur­ing re­port. Check out the chan­nel here and vis­it your read­er pro­file to re­ceive it in your in­box next Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER